Therapeutic Implications of the Drug Resistance Conferred by Extracellular Vesicles Derived from Triple-Negative Breast Cancer Cells

Int J Mol Sci. 2023 Feb 12;24(4):3704. doi: 10.3390/ijms24043704.

Abstract

Anticancer drug resistance is a significant impediment in current cancer treatment. Extracellular vesicles (EVs) derived from cancer cells were recently acknowledged as a critical mechanism of drug resistance, tumor progression, and metastasis. EVs are enveloped vesicles comprising a lipid bilayer that transfers various cargo, including proteins, nucleic acids, lipids, and metabolites, from an originating cell to a recipient cell. Investigating the mechanisms whereby EVs confer drug resistance is still in the early stages. In this review, I analyze the roles of EVs derived from triple-negative breast cancer cells (TNBC-EVs) in anticancer drug resistance and discuss strategies to overcome TNBC-EV-mediated drug resistance.

Keywords: anticancer therapeutics; drug resistance; exosomes; extracellular vesicles; triple-negative breast cancer; tumor cell-derived extracellular vesicles.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / metabolism
  • Cell Communication
  • Drug Resistance, Neoplasm
  • Extracellular Vesicles* / metabolism
  • Humans
  • Triple Negative Breast Neoplasms* / metabolism

Substances

  • Antineoplastic Agents